Cheung Eric Yuk Hong, Ng Rebecca Yuen Ting, Yu Simon Chun Ho, Zhuang James Tin Fong, Wong George Kwok Chu
Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Department of Neurosurgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
Neurointervention. 2022 Nov;17(3):174-182. doi: 10.5469/neuroint.2022.00199. Epub 2022 Aug 30.
Precipitating hydrophobic injectable liquid (PHIL; MicroVention, Aliso Viejo, CA, USA) and Squid (Balt, Irvine, CA, USA) are 2 newer liquid embolic agents used in endovascular embolization of cerebral arteriovenous malformation (AVM). This study aims to investigate and compare the effectiveness and safety profile of the 2 newer liquid embolic agents in the embolization of cerebral AVM. This is a retrospective study on all patients diagnosed with cerebral AVM undergoing endovascular embolization with liquid embolic agents PHIL and Squid admitted to the Division of Neurosurgery, Department of Surgery in Prince of Wales Hospital from January 2014 to June 2021. Twenty-three patients with cerebral AVM were treated with 34 sessions of endovascular embolization with either PHIL or Squid (17 sessions each) liquid embolic agents with a male to female ratio of 2.3:1 (male 16; female 7) and mean age of 44.6 (range, 12 to 67). The mean total nidus obliteration rate per session was 57% (range, 5% to 100%). Twenty-one patients (91.3%) received further embolization, stereotactic radiosurgery, or surgical excision after initial endovascular embolization. There were 2 morbidities (1 neurological and 1 non-neurological, 6%) and no mortalities (0%). All patients had static or improvement in modified Rankin Scale at 3 to 6 months at discharge. PHIL and Squid are effective and safe liquid embolic agents for endovascular embolization of cerebral AVM, achieving satisfactory nidal obliteration rates and patient functional outcomes.
沉淀型疏水可注射液体（PHIL；美国加利福尼亚州阿利索维耶霍市的MicroVention公司）和鱿鱼胶（美国加利福尼亚州欧文市的Balt公司）是用于脑动静脉畸形（AVM）血管内栓塞的2种新型液体栓塞剂。本研究旨在调查和比较这2种新型液体栓塞剂在脑AVM栓塞中的有效性和安全性。这是一项回顾性研究，研究对象为2014年1月至2021年6月在威尔士亲王医院外科神经外科接受使用液体栓塞剂PHIL和鱿鱼胶进行血管内栓塞治疗的所有诊断为脑AVM的患者。23例脑AVM患者接受了34次血管内栓塞治疗，使用的是PHIL或鱿鱼胶（各17次）液体栓塞剂，男女比例为2.3:1（男性16例；女性7例），平均年龄为44.6岁（范围12至67岁）。每次治疗的平均总病灶闭塞率为57%（范围5%至100%）。21例患者（91.3%）在初次血管内栓塞后接受了进一步的栓塞、立体定向放射外科治疗或手术切除。有2例并发症（1例神经并发症和1例非神经并发症，6%），无死亡病例（0%）。所有患者出院时3至6个月的改良Rankin量表评分保持稳定或有所改善。PHIL和鱿鱼胶是用于脑AVM血管内栓塞的有效且安全的液体栓塞剂，可实现令人满意的病灶闭塞率和患者功能预后。
